Thienotriazolodiazepine compound and medicinal use thereof

A thienotriazolodiazepine compound represented by the formula (I)

• wherein
• R1 is hydrogen atom, halogen atom, C1-6 alkyl optionally substituted by halogen atom or hydroxyl group, or —(CH2)kORa (k is an integer of 1 to 4, and Ra is C1-6 alkyl optionally having substituent(s)),
• R20 is C1-6 alkyl,
• R2 is hydrogen atom, or the following formula (a)
• wherein R4 is C1-6 alkyl optionally having substituent(s), and m is an integer of 1 to 4,
• R21 is methyl or hydroxymethyl, and
• R3 is
• when R2 is a hydrogen atom, then C6-12 aryl optionally having one or more substituents selected from halogen atom, cyano, acetyl, hydroxymethyl, hydroxyethyl, methoxy and hydroxyl group;
• pyridyl, thienyl, thiazolyl, pyrimidinyl, or pyrazolyl, each of which optionally has one or more substituents selected from acetyl, hydroxymethyl, hydroxyethyl, cyano, amino, methyl and halogen atom;
• or —NR5—(CH2)n—R6 (R5 is hydrogen atom or methyl, n is an integer of 0 to 3, and R6 is C6-12 aryl optionally having one or more substituents selected from halogen atom, hydroxyl group, methoxy, methylenedioxy and cyano;
• or pyridyl, thiazolyl, isoxazolyl, pyrazolyl, tetrahydrofuranyl or tetrahydropyranyl, each of which optionally has substituents one or more selected from methyl optionally substituted by halogen atom, cyano, halogen atom and methoxy), and
• when R2 is the formula (a), then C6-12 aryl optionally having substituent(s), heteroaryl having 5 to 12 ring-constituting atoms and optionally having substituent(s), arylcarbonyl alkyl (the aryl moiety has 6 to 12 carbon atoms, and the alkyl moiety has 1 to 6 carbon atoms) optionally having substituent(s) on the ring, —NR5a—(CH2)o—R6a (R5a is hydrogen atom or C1-6 alkyl optionally having substituent(s), o is an integer of 0 to 4, and R6a is C6-12 aryl optionally having substituent(s), C7-13 arylcarbonyl optionally having substituent(s), C6-12 aryloxy optionally having substituent(s) or heteroaryl having 5 to 12 ring-constituting atoms and optionally having substituent(s)), or a group selected by following
• wherein
• R7 and R7′ are the same or different and each is hydrogen atom, C1-6 alkyl optionally having substituent(s) or C1-6 alkoxy optionally having substituent(s),
• ring A is cyclic amine having 4 or 5 carbon atoms, which is condensed with aromatic ring,
• R8 is C6-12 aryl optionally having substituent(s), heteroaryl having 5 to 12 ring-constituting atoms and optionally having substituent(s), C7-18 aralkyl optionally having substituent(s), C7-13 arylcarbonyl optionally having substituent(s) or heteroarylcarbonyl having 5 to 12 ring-constituting atoms and optionally having substituent(s),
• R9 is hydrogen atom, hydroxyl group or cyano group,
• R10 is C1-6 alkyl optionally having substituent(s), C6-12 aryl optionally having substituent(s) or heteroaryl having 5 to 12 ring-constituting atoms and optionally having substituent(s),
• R11 is C6-12 aryl optionally having substituent(s), heteroaryl having 5 to 12 ring-constituting atoms and optionally having substituent(s) or anilinocarbonyl optionally having substituent(s),
• R12 is heteroaryl having 5 to 12 ring-constituting atoms and optionally having substituent(s),
• R13 is hydrogen atom or C1-6 alkyl optionally having substituent(s),
• p is an integer of 0 to 2,
• R14 is C6-12 aryl optionally having substituent(s) or heteroaryl having 5 to 12 ring-constituting atoms and optionally having substituent(s),
• R15 is hydrogen atom or C1-6 alkyl optionally having substituent(s),
• R16 is C6-12 aryl optionally having substituent(s) or heteroaryl having 5 to 12 ring-constituting atoms and optionally having substituent(s),
• R17 is hydrogen atom or C1-6 alkyl optionally having substituent(s),
• R18 is C6-12 aryl optionally having substituent(s) or C7-18 aralkyl, and
• R19 is C6-12 aryl optionally having substituent(s) or heteroaryl having 5 to 12 ring-constituting atoms and optionally having substituent(s),
• or a pharmaceutically acceptable salt thereof.